Tuberculosis (TB) continues to impose large health and socio‑economic burdens in Africa, with severe illness affecting millions annually. The complexity of multi‑drug TB treatment and variable patient responses motivate efforts to personalise therapy. Adjusting isoniazid (INH) dosing by NAT2 genotype is an example of a genotype‑guided approach that could improve outcomes at scale. However, fully addressing treatment response requires broader consideration of the pharmacogenomic (PGx) landscape, especially in African populations that are genetically diverse and historically understudied.
This study aimed to predict NAT2 genotypes and phenotypes in specific African populations and to extend TB pharmacogenomics research beyond established biomarkers by evaluating variation across multiple ADME and PGx genes using in‑silico tools.
The analysis used next‑generation sequencing data from 2,143 individuals representing 20 distinct African population groups. The genomic data spanned ten genes implicated in absorption, distribution, metabolism and excretion (ADME) or otherwise associated with multi‑drug TB treatment and response. Population identifiers included, but were not limited to, groups such as the Khomani and Nama.
Current bioinformatic prediction tools were applied to the individual‑ and population‑level sequencing data to evaluate predicted functional consequences of observed variants. The approach focused on detecting predicted functionally deleterious alleles within the selected PGx and ADME genes and on translating NAT2 genotypes into metabolizer phenotypes that have clinical relevance for INH exposure.
The manuscript describes the use of established in‑silico algorithms to infer functional impact, noting that these tools form the basis of the reported predictions. Specific tool names and detailed algorithmic parameters were not listed in the source text.
Most variants predicted to be functionally deleterious were rare, with minor allele frequency (MAF) below 0.01. Additionally, many of these rare predicted deleterious variants were observed in only one of the 20 population groups, demonstrating a largely population‑specific distribution of low‑frequency ADME variants.
This pattern underlines that, in these African cohorts, the cumulative PGx signal includes numerous rare alleles whose predicted effects are not widely shared across groups.
From the predicted NAT2 genotypes, metabolizer phenotypes were inferred for each population group. The Khomani and Nama populations were notable for a distinctly higher proportion of NAT2 fast metabolizer phenotypes compared with the other African populations included in the study.
A higher frequency of fast metabolizer phenotypes implies relatively faster acetylation of INH and a lower risk of drug overexposure, which can have implications for optimal dosing strategies in these groups.
The observed variation in NAT2 phenotype frequencies between populations suggests potential heterogeneity in INH pharmacokinetics and risk of adverse exposure across African groups. Specifically, populations with higher proportions of fast metabolizers, such as Khomani and Nama, may have different dosing considerations than populations with more slow or intermediate metabolizer phenotypes.
The authors frame these results as supportive of genotype‑informed dosing approaches but emphasise that broader PGx context and validation are necessary before clinical implementation.
The study highlights limitations in functional prediction for ADME variants. Key constraints include the predominance of rare predicted deleterious alleles, population specificity of many variants, and the limited transferability of in‑silico predictions between diverse African groups.
These limitations reflect both the current state of bioinformatic prediction algorithms and the incomplete representation of African genetic diversity in public variant databases, which affects confidence in predicted functional outcomes and their generalisability.
The findings underscore the potential of integrating next‑generation sequencing and improved computational tools to characterise the cumulative genetic contribution to TB drug response. Expanded sequencing efforts, the development of comprehensive databases that capture African variation, and advances in predictive algorithms are cited as necessary steps to more accurately inform precision treatment strategies for TB in African settings.
Until such resources and validations are available, caution is advised when extrapolating predicted functional impacts across populations or applying genotype‑guided dosing protocols broadly.
The authors report that all relevant ethical guidelines were followed and that necessary institutional review board approvals and participant consents were obtained. Specific project and ethics reference numbers were provided in the source text. The authors state that all data produced in the study are available upon reasonable request, and that data produced are contained in the manuscript. Funding sources declared include the South African Medical Research Council and a GSK grant identifier reported in the manuscript.
No competing interests were declared by the authors.
Using in‑silico tools on next‑generation sequencing data from 2,143 individuals across 20 African populations, this study identified primarily rare, population‑specific predicted deleterious ADME variants and documented population differences in NAT2 metabolizer phenotypes. The Khomani and Nama populations had a higher proportion of NAT2 fast metabolizers, which may influence isoniazid exposure risk and dosing considerations. The work emphasises both the promise of genomics for precision TB therapy and current limitations in functional prediction and cross‑population transferability. The authors call for expanded sequencing, better African‑focused variant resources, and improved computational methods to enhance prediction accuracy and inform precision TB treatment strategies.